Enhancing a Wnt-Telomere Feedback Loop Restores Intestinal Stem Cell Function in a Human Organotypic Model of Dyskeratosis Congenita

Cell Stem Cell

Volumn 19, Issue 3, 2016, Pages 397-405

  Woo, Dong Hun ^a   Chen, Qijun ^b   Yang, Ting Lin B ^a,b   Glineburg, M Rebecca ^a,b   Hoge, Carla ^a   Leu, Nicolae A ^a   Johnson, F Brad ^a,b   Lengner, Christopher J ^a,b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

6 [[2 [[4 (2,4 DICHLOROPHENYL) 5 (4 METHYL 1H IMIDAZOL 2 YL) 2 PYRIMIDINYL]AMINO]ETHYL]AMINO]NICOTINONITRILE; DYSKERIN; LITHIUM CHLORIDE; TELOMERIC REPEAT BINDING FACTOR 2; WNT PROTEIN; LITHIUM; TERF2 PROTEIN, HUMAN;

ALLELE; ANIMAL EXPERIMENT; ARTICLE; CELL DIFFERENTIATION; CELL FUNCTION; CELL MATURATION; CONTROLLED STUDY; CRISPR CAS SYSTEM; CYTOPLASM; DYSKERATOSIS CONGENITA; FIBROBLAST; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; INDUCED PLURIPOTENT STEM CELL; INTESTINAL STEM CELL; INTESTINAL TISSUE; KIDNEY CAPSULE; MALE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; STEM CELL SELF-RENEWAL; TELOMERE; WNT SIGNALING PATHWAY; XENOGRAFT; ANIMAL; BIOLOGICAL MODEL; CYTOLOGY; DRUG EFFECTS; HEK293 CELL LINE; INTESTINE; METABOLISM; MOUSE; NUCLEOTIDE SEQUENCE; PATHOLOGY; PHYSIOLOGICAL FEEDBACK; STEM CELL;

ANIMALS; BASE SEQUENCE; CELL DIFFERENTIATION; DYSKERATOSIS CONGENITA; FEEDBACK, PHYSIOLOGICAL; HEK293 CELLS; HUMANS; INTESTINES; LITHIUM; MICE; MODELS, BIOLOGICAL; ORGANOIDS; PHENOTYPE; STEM CELLS; TELOMERE; TELOMERIC REPEAT BINDING PROTEIN 2; WNT SIGNALING PATHWAY;

EID: 84991067502     PISSN: 19345909     EISSN: 18759777     Source Type: Journal    
DOI: 10.1016/j.stem.2016.05.024     Document Type: Article

References (27)

1. Agarwal, S., Loh, Y.H., McLoughlin, E.M., Huang, J., Park, I.H., Miller, J.D., Huo, H., Okuka, M., Dos Reis, R.M., Loewer, S., et al. Telomere elongation in induced pluripotent stem cells from dyskeratosis congenita patients. Nature 464 (2010), 292–296.
2. Armanios, M., Blackburn, E.H., The telomere syndromes. Nat. Rev. Genet. 13 (2012), 693–704.
3. Batista, L.F., Pech, M.F., Zhong, F.L., Nguyen, H.N., Xie, K.T., Zaug, A.J., Crary, S.M., Choi, J., Sebastiano, V., Cherry, A., et al. Telomere shortening and loss of self-renewal in dyskeratosis congenita induced pluripotent stem cells. Nature 474 (2011), 399–402.
4. Berezin, S., Schwarz, S.M., Slim, M.S., Beneck, D., Brudnicki, A.R., Medow, M.S., Gastrointestinal problems in a child with dyskeratosis congenita. Am. J. Gastroenterol. 91 (1996), 1271–1272.
5. Borggraefe, I., Koletzko, S., Arenz, T., Fuehrer, M., Hoffmann, F., Dokal, I., Vulliamy, T., Weiler, V., Griese, M., Belohradsky, B.H., Lang, T., Severe variant of x-linked dyskeratosis congenita (Hoyeraal-Hreidarsson syndrome) causes significant enterocolitis in early infancy. J. Pediatr. Gastroenterol. Nutr. 49 (2009), 359–363.
6. Brown, K.E., Kelly, T.E., Myers, B.M., Gastrointestinal involvement in a woman with dyskeratosis congenita. Dig. Dis. Sci. 38 (1993), 181–184.
7. Diala, I., Wagner, N., Magdinier, F., Shkreli, M., Sirakov, M., Bauwens, S., Schluth-Bolard, C., Simonet, T., Renault, V.M., Ye, J., et al. Telomere protection and TRF2 expression are enhanced by the canonical Wnt signalling pathway. EMBO Rep. 14 (2013), 356–363.
8. Dokal, I., Dyskeratosis congenita in all its forms. Br. J. Haematol. 110 (2000), 768–779.
9. Fernández García, M.S., Teruya-Feldstein, J., The diagnosis and treatment of dyskeratosis congenita: a review. J. Blood Med. 5 (2014), 157–167.
10. Gu, B.W., Apicella, M., Mills, J., Fan, J.M., Reeves, D.A., French, D., Podsakoff, G.M., Bessler, M., Mason, P.J., Impaired telomere maintenance and decreased canonical WNT signaling but normal ribosome biogenesis in induced pluripotent stem cells from X-linked dyskeratosis congenita patients. PLoS ONE, 10, 2015, e0127414.
11. Hao, L.Y., Armanios, M., Strong, M.A., Karim, B., Feldser, D.M., Huso, D., Greider, C.W., Short telomeres, even in the presence of telomerase, limit tissue renewal capacity. Cell 123 (2005), 1121–1131.
12. Herbig, U., Jobling, W.A., Chen, B.P., Chen, D.J., Sedivy, J.M., Telomere shortening triggers senescence of human cells through a pathway involving ATM, p53, and p21(CIP1), but not p16(INK4a). Mol. Cell 14 (2004), 501–513.
13. Hockemeyer, D., Palm, W., Wang, R.C., Couto, S.S., de Lange, T., Engineered telomere degradation models dyskeratosis congenita. Genes Dev. 22 (2008), 1773–1785.
14. Hoffmeyer, K., Raggioli, A., Rudloff, S., Anton, R., Hierholzer, A., Del Valle, I., Hein, K., Vogt, R., Kemler, R., Wnt/β-catenin signaling regulates telomerase in stem cells and cancer cells. Science 336 (2012), 1549–1554.
15. Jonassaint, N.L., Guo, N., Califano, J.A., Montgomery, E.A., Armanios, M., The gastrointestinal manifestations of telomere-mediated disease. Aging Cell 12 (2013), 319–323.
16. Leroy, K., Ando, K., Héraud, C., Yilmaz, Z., Authelet, M., Boeynaems, J.M., Buée, L., De Decker, R., Brion, J.P., Lithium treatment arrests the development of neurofibrillary tangles in mutant tau transgenic mice with advanced neurofibrillary pathology. J. Alzheimers Dis. 19 (2010), 705–719.
17. Mason, P.J., Bessler, M., The genetics of dyskeratosis congenita. Cancer Genet. 204 (2011), 635–645.
18. Nera, B., Huang, H.S., Lai, T., Xu, L., Elevated levels of TRF2 induce telomeric ultrafine anaphase bridges and rapid telomere deletions. Nat. Commun., 6, 2015, 10132.
19. O'Brien, W.T., Harper, A.D., Jové, F., Woodgett, J.R., Maretto, S., Piccolo, S., Klein, P.S., Glycogen synthase kinase-3beta haploinsufficiency mimics the behavioral and molecular effects of lithium. J. Neurosci. 24 (2004), 6791–6798.
20. Oruch, R., Elderbi, M.A., Khattab, H.A., Pryme, I.F., Lund, A., Lithium: a review of pharmacology, clinical uses, and toxicity. Eur. J. Pharmacol. 740 (2014), 464–473.
21. Ran, F.A., Hsu, P.D., Lin, C.Y., Gootenberg, J.S., Konermann, S., Trevino, A.E., Scott, D.A., Inoue, A., Matoba, S., Zhang, Y., Zhang, F., Double nicking by RNA-guided CRISPR Cas9 for enhanced genome editing specificity. Cell 154 (2013), 1380–1389.
22. Savage, S.A., Human telomeres and telomere biology disorders. Prog. Mol. Biol. Transl. Sci. 125 (2014), 41–66.
23. Spence, J.R., Mayhew, C.N., Rankin, S.A., Kuhar, M.F., Vallance, J.E., Tolle, K., Hoskins, E.E., Kalinichenko, V.V., Wells, S.I., Zorn, A.M., et al. Directed differentiation of human pluripotent stem cells into intestinal tissue in vitro. Nature 470 (2011), 105–109.
24. Tao, S., Tang, D., Morita, Y., Sperka, T., Omrani, O., Lechel, A., Sakk, V., Kraus, J., Kestler, H.A., Kühl, M., Rudolph, K.L., Wnt activity and basal niche position sensitize intestinal stem and progenitor cells to DNA damage. EMBO J. 34 (2015), 624–640.
25. Watson, C.L., Mahe, M.M., Múnera, J., Howell, J.C., Sundaram, N., Poling, H.M., Schweitzer, J.I., Vallance, J.E., Mayhew, C.N., Sun, Y., et al. An in vivo model of human small intestine using pluripotent stem cells. Nat. Med. 20 (2014), 1310–1314.
26. Womer, R., Clark, J.E., Wood, P., Sabio, H., Kelly, T.E., Dyskeratosis congenita: two examples of this multisystem disorder. Pediatrics 71 (1983), 603–609.
27. Wong, J.M., Collins, K., Telomerase RNA level limits telomere maintenance in X-linked dyskeratosis congenita. Genes Dev. 20 (2006), 2848–2858.